Surgical treatment of hereditary breast cancer

doi:10.16139/j.1007-9610.2022.05.003

Abstract

CLC Number:

R737.9

CHEN Yiding, WU Shijie. Surgical treatment of hereditary breast cancer[J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 392-395.

References 27

[1]	Chen W, Zheng R, Baade P, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[2]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[3]	Hu C, Hart SN, Gnanaolivu R, et al. A population-based study of genes previously implicated in breast cancer[J]. N Engl J Med, 2021, 384(5):440-451.
[4]	Breast Cancer Association Consortium, Dorling L, Carvalho S, et al. Breast cancer risk genes - association analysis in more than 113,000 women[J]. N Engl J Med, 2021, 384(5):428-439.
[5]	Kurian AW, Ward KC, Abrahamse P, et al. Time trends in receipt of germline genetic testing and results for women diagnosed with breast cancer or ovarian cancer, 2012-2019[J]. J Clin Oncol, 2021, 39(15):1631-1640.
[6]	Sun J, Meng H, Yao L, et al. Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients[J]. Clin Cancer Res, 2017, 23(20):6113-6119.
[7]	Deng M, Chen HH, Zhu X, et al. Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China[J]. Int J Cancer, 2019, 145(6):1517-1528.
[8]	Liu Y, Wang H, Wang X, et al. Prevalence and reclassification of BRCA1 and BRCA2 variants in a large, unselected Chinese Han breast cancer cohort[J]. J Hematol Oncol, 2021, 14(1):18.
[9]	Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers[J]. JAMA, 2017, 317(23):2402-2416.
[10]	Ducy M, Sesma-Sanz L, Guitton-Sert L, et al. The tumor suppressor PALB2: inside out[J]. Trends Biochem Sci, 2019, 44(3):226-240.
[11]	Zhou J, Wang H, Fu F, et al. Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing[J]. Cancer, 2020, 126(14):3202-3208.
[12]	Cybulski C, Kluzniak W, Huzarski T, et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis[J]. Lancet Oncol, 2015, 16(6):638-644.
[13]	Yang X, Leslie G, Doroszuk A, et al. Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families[J]. J Clin Oncol, 2020, 38(7):674-685.
[14]	Pierce LJ, Phillips KA, Griffith KA, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy[J]. Breast Cancer Res Treat, 2010, 121(2):389-398.
[15]	Nilsson MP, Hartman L, Kristoffersson U, et al. High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer[J]. Breast Cancer Res Treat, 2014, 147(3):571-578.
[16]	Cao W, Xie Y, He Y, et al. Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer follow-ing breast-conserving surgery with BRCA1 and BRCA2 mutation in China[J]. Breast Cancer Res Treat, 2019, 175(3):749-754.
[17]	van den Broek AJ, Schmidt MK, van′t Veer LJ, et al. Prognostic impact of breast-conserving therapy versus mastectomy of BRCA1/2 mutation carriers compared with noncarriers in a consecutive series of young breast cancer patients[J]. Ann Surg, 2019, 270(2):364-372.
[18]	Wan Q, Su L, Ouyang T, et al. Comparison of survival after breast-conserving therapy vs. mastectomy among patients with or without the BRCA1/2 variant in a large series of unselected Chinese patients with breast cancer[J]. JAMA Netw Open, 2021, 4(4):e216259.
[19]	Manning AT, Wood C, Eaton A, et al. Nipple-sparing mastectomy in patients with BRCA1/2 mutations and variants of uncertain significance[J]. Br J Surg, 2015, 102(11):1354-1359.
[20]	Yao K, Liederbach E, Tang R, et al. Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature[J]. Ann Surg Oncol, 2015, 22(2):370-376.
[21]	Kaas R, Verhoef S, Wesseling J, et al. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer[J]. Ann Surg, 2010, 251(3):488-492.
[22]	Carbine NE, Lostumbo L, Wallace J, et al. Risk-reducing mastectomy for the prevention of primary breast cancer[J]. Cochrane Database Syst Rev, 2018, 4(4):CD002748.
[23]	Evron E, Ben-David AM, Goldberg H, et al. Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer[J]. Ann Oncol, 2019, 30(3):412-417.
[24]	Tung NM, Boughey JC, Pierce LJ, et al. Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline[J]. J Clin Oncol, 2020, 38(18):2080-2106.
[25]	Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A, et al. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis[J]. Ann Oncol, 2013, 24(8):2029-2035.
[26]	O′Connell RL, Tasoulis MK, Hristova E, et al. Satisfaction with long-term aesthetic and 10 years oncologic outcome following risk-reducing mastectomy and implant-based breast reconstruction with or without nipple preservation[J]. Cancers (Basel), 2022, 14(15):3607.
[27]	中国抗癌协会家族遗传性肿瘤专业委员会. 中国家族遗传性肿瘤临床诊疗专家共识(2021年版)(1)—家族遗传性乳腺癌[J]. 中国肿瘤临床, 2021, 48(23):1189-1195.

Surgical treatment of hereditary breast cancer

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 27

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHU Qiaoli, MIAO Yiming, CHEN Xiaosong. Prognostic analysis of breast-conserving surgery or mastectomy in patients with stage Ⅰ-Ⅲ triple-negative breast cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 371-377.
[2]	YANG Yi, YANG Xingxia, JIN Sili, ZHANG Xu, ZHU Juanying, CHEN Xiaosong. Clinical application of preoperative MRI examination in breast-conserving surgery for ductal carcinoma in situ [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 378-382.
[3]	DONG Jun, CUI Fengming, LIU Jun. Effects of silencing Ki-67 gene on doxorubicin resistance of breast cancer MCF-7/DOX cells [J]. Journal of Surgery Concepts & Practice, 2023, 28(03): 254-259.
[4]	GAO Weiqi, ZHANG Xu, WANG Zheng, ZHU Yifei, HUANG Jiahui, HONG Jin, ZHU Siji, CHEN Xiaosong, HUANG Ou, HE Jianrong, CHEN Weiguo, LI Yafen, SHEN Kunwei, XU Hua, WU Jiayi. Safety analysis of immediate breast reconstruction with deep inferior epigastric perforator after neoadjuvant treatment [J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 147-151.
[5]	WU Jiayi, LU Yujie, HE Jinguang, SHEN Kunwei, XU Hua. Post-mastectomy implant-based breast reconstruction [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 387-391.
[6]	CHEN Xiaosong, SHEN Kunwei, Ll Hongwei. Diagnosis and treatment in early operable breast cancer: current status and prospect [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 385-386.
[7]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 396-402.
[8]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 403-405.
[9]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 406-410.
[10]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 411-415.
[11]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 416-420.
[12]	YANG Cuiyan, WANG Haoyu, CHEN Xiaosong, SHEN Kunwei. Study on tumour suppressor gene TP53 mutation and prognosis in patients with triple-negative breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 421-428.
[13]	PAN Ruixin, CHEN Xiaosong, SHEN Kunwei. Study on circulating tumor DNA and circulating tumor cell detecting minimal residual disease in breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 463-467.
[14]	ZHU Siyi, CHEN Xiaosong, SHEN Kunwei. Study on obesity associated with prognosis of early breast cancer and efficacy of adjuvant therapy [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 468-472.
[15]	WANG Jieqiang, MA Dekui. Study on trophoblast cell-surface antigen 2 gene and triple-negative breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 473-477.